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Citrus bergamia Risso et Poiteau, also known as “Bergamot,” is a plant belonging to the
Rutaceae family, deﬁned as a hybrid of bitter orange and lemon. It is an endemic plant of the
Calabria region (Italy). Bergamot fruit is primarily used for the extraction of its essential oil
(bergamot essential oil: BEO), employed in perfume, cosmetics, food, and confections.The
aim of this review was to collect recent data from the literature on C. bergamia essential oil
and, through a critical analysis, focus on safety and the beneﬁcial effects on human health.
Clinical studies on the therapeutic applications of BEO exclusively focus on the ﬁeld of
aromatherapy, suggesting that its use can be useful for reducing anxiety and stress.
Keywords: Citrus bergamia, bergamot essential oil, natural products, complementary and alternative medicine,
aromatherapy
INTRODUCTION
Bergamot is the common name for Citrus bergamia Risso et
Poiteau, a plant belonging to the Rutaceae family (subfamily
Esperidea). The trees show big dark green ovate leaves similar
to those of lemon, star shaped white ﬂowers and round yellow
fruits. The botanical and geographical origins of this plant are
still uncertain (Rapisarda and Germanò, 2013). It may be native
of the Calabria region (Italy), as a result of mutations from other
species. Alternatively, it may originate from Antilles, Greece, and
the Canary Islands, from where Christopher Columbus imported
it. Thename“bergamot”seems to be derived fromBerga, the Span-
ish city from which the plant was transported in Calabria (south
of Italy) later. C. bergamia trees are cultivated almost exclusively
along the southern coast of the Calabria region (more than 90% of
the world production of bergamot comes from this region). How-
ever, small numbers of bergamot plants grow in other countries,
such as Greece, Morocco, Iran and Ivory Coast, Argentina, and
Brazil.
Citrus bergamia is deﬁned as a hybrid between a sour orange
(C. aurantium L.) and lemon (C. limon L. Burm. f.) or a mutation
of the latter. Other authors considered it a hybrid between a sour
orange and lime (C. aurantifolia [Christm. and Panzer] Swingle;
Rapisarda and Germanò, 2013). Bergamot fruit is mainly used for
its essential oils (bergamot essential oil: BEO) that are obtained by
rasping and cold pressing the fruit peel. BEO is widely used in per-
fume, cosmetics, food, and confectionery industries for its intense
fragrance and freshness. BEO is a greenish or brownish-yellow
volatile oil (corresponding to the beginning and the end of the
productive season) with a bitter aromatic taste and a characteristic
pleasant odor. It is included in various countries’ ofﬁcial Pharma-
copoeias. However, bergamot juice, obtained from the endocarp
after essential oils extraction, has long time been considered just
a secondary and discarded product of the essential oil industry
due to its bitter taste. Recently, it gained attention because of
its hypolipemic and hypoglycaemic activity (Mollace et al., 2011),
as well as its anti-inﬂammatory (Impellizzeri et al., 2014; Risitano
et al., 2014) and anti-cancer properties (DelleMonache et al., 2013;
Navarra et al., 2014; Visalli et al., 2014).
BEO CHEMICAL COMPOSITION
The chemical composition of BEO has been widely investigated
and is well known (Costa et al., 2010; Dugo and Bonaccorsi, 2013).
BEO contains several bioactive molecules with potential health
beneﬁts. It is composed of both a volatile (93–96% of total) and
a non-volatile (4–7% of total) fraction. The ﬁrst is mainly repre-
sentedbymonoterpene and sesquiterpenehydrocarbons, and their
oxygenated derivatives, along with aliphatic aldehydes, alcohols,
and esters (Dugo and Bonaccorsi, 2013). They include monoter-
pene limonene (25–53%) and high quantities of oxygenated
compounds, such as linalool (2–20%), linalyl acetate (15–40%),γ-
terpinene, and β-pinene (Mondello et al., 1998). The non-volatile
fraction (4–7%of total) contains pigments, waxes, coumarins, and
psoralens (such as 5-methoxypsoralen, also known as bergapten
or 5-MOP, contained in about 0.2%), as well as bergamottine [5-
geranyloxypsoralen]) (Dugo et al., 2000). Due to the well-known
5-MOP-induced photo-toxicity, a furocoumarins-free essential oil
has been prepared for perfumery and cosmetic uses. The vacuum
distillation of bergamot peels provides a high-quality BEO totally
devoid of 5-MOP that is chemically comparable to that of the
cold-pressed oil (Belsito et al., 2007).
The characteristic ﬂavor of Citrus oils is mainly provided by
linalool, citral, and linalyl acetate, (Fang et al., 2004), whereas
limonene andpinene are notmuchﬂavoring and they are relatively
unstable compounds when exposed to heat and light. Thus, it is
necessary to remove them to increase the shelf life of the products
(Reverchon and Iacuzio, 1997; Fang et al., 2004).
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BEO INDUSTRIAL AND MEDICINAL USES
Bergamot essential oil is one of the main basic constituents for
the manufacture of perfumes, due to its ability to ﬁx the aromatic
bouquet of aromas and harmonize all of the essences, enhancing
the fragrance. BEO is also used by the pharmaceutical industry,
both to absorb the unpleasant smells of medicinal products and
for its antiseptic and antibacterial properties. Finally, BEO is used
in the food and confectionery industries as a ﬂavoring.
In Italian folk medicine, it has been used primarily for fever
and parasitic diseases, in addition to mouth, skin, respiratory
and urinary tract infections, gonococcal infections, leucorrhoea,
vaginal pruritus, tonsillitis, and sore throats (Pendino, 1998). For
its antiseptic and antibacterial proprieties, BEO has been used as
an antimicrobial agent to facilitate wound healing and has been
included in preparations used to treat upper respiratory-tract dis-
orders and hyperhidrosis. Moreover, BEO’s use in magisterial,
handcrafted, and homemade medicaments that were useful for
skin disinfection, as well as use as an aid for healingminorwounds,
has a long tradition in Italy. Currently, a furocoumarins-free BEO
is used in preparations for cutaneous use.
Bergamot essential oil is widely employed in aromatherapy, and
has recently received renewed popularity in improving mood and
mild symptoms of stress-induced disorders (Halcon, 2002) and
facilitating sleep induction (Wiebe, 2000). Aromatherapy massage
has been shown to relieve symptoms of anxiety in patients with
cancer (Wilkinson et al., 2007).
BIOLOGICAL ACTIVITIES OF BEO
ANTIMICROBIAL ACTIVITY
It has been reported that BEO has both antibacterial and anti-
fungal activity against Campylobacter jejuni, Escherichia coli O157,
Listeria monocytogenes, Bacillus cereus, and Staphylococcus aureus
and dermatophytes, respectively (Karaca et al., 2007). The in vitro
activity of BEO against Candida species suggests BEO’s potential
role in the topical treatment of Candida infections (Romano et al.,
2005). BEO is also active against dermatophytes in vitro (San-
guinetti et al., 2007). Additionally, chitosan-based ﬁlms containing
BEO at 0.5, 1, 2, and 3% w/w showed a signiﬁcant dose-dependent
inhibitory effect on the growth of Penicillium italicum (Sánchez-
González et al., 2010). Moreover, the in vitro effectiveness of the
oil and vapors of bergamot and its components against common
foodborne pathogens has been also investigated, and linalool was
revealed to be the most effective anti-bacterial component (Fisher
and Phillips, 2006).
ANTI-INFLAMMATORY ACTIVITY
Bergamot essential oil anti-inﬂammatory activity was demon-
strated using the carrageenan-induced rat paw oedema test. The
highest level of BEO anti-inﬂammatory activity was obtained with
a 0.10 ml/kg dosage. The median effective dose of BEO was found
to be 0.079 ml/kg (Karaca et al., 2007).
ANTIPROLIFERATIVE ACTIVITY
Bergamot essential oil has also been found to inhibit the survival
and proliferation of SH-SY5Y neuroblastoma cells, (Celia et al.,
2013) through the activation of multiple pathways leading to both
necrotic and apoptotic cell death (Ursino et al., 2010). Moreover,
Russo et al. (2013) showed that association of limonene and linalyl
acetate, but not the exposure to the single compounds, caused sig-
niﬁcant cytotoxicity, suggesting for a major role of the combined
action of these monoterpenes in cancer cell death induced by BEO.
NEUROPSYCHOPHARMACOLOGICAL AND NEUROPROTECTIVE
ACTIVITIES
Anxiolytic effects of BEO (1.0, 2.5, and 5.0% w/w) were studied by
administering it to rats subjected to anxiety-related behaviors, the
elevated plus-maze and the hole-board tests, and then measuring
the stress-induced levels of plasma corticosterone in comparison
with the effects of diazepam. BEO (2.5%) and diazepam exhibited
anxiolytic-like effects and attenuated the corticosterone response
to acute stress (Saiyudthong and Marsden, 2010).
After perfusion into the hippocampus via the dialysis probe
(20 μl/20 min), BEO produced a dose-dependent and Ca2+-
independent increase of extracellular aspartate, glycine, taurine,
GABA, and glutamate (Morrone et al., 2007). Moreover, BEO
(0.5 ml/kg) given intraperitoneally 1 h before experimental occlu-
sion of the middle cerebral artery, signiﬁcantly reduced infarct size
after 24 h, especially in the medial striatum and the motor cor-
tex, as revealed by 2,3,5-triphenyl-2H-tetrazolium chloride (TTC)
staining of tissue slices (Amantea et al., 2009).
Finally, in the humanSH-SY5Yneuroblastoma cell line exposed
to N-methyl-D-aspartate (NMDA), BEO (0.0005–0.01%) reduced
the death of SH-SY5Y cells caused by 1 mM NMDA in a concen-
tration dependent manner. In addition, 0.01% BEO counteracted
the deactivation of Akt (a serine/threonine-speciﬁc protein kinase)
and the consequent activation of glycogen synthase kinase 3 beta
(GSK-3B) induced by NMDA. Results obtained with speciﬁc frac-
tions of BEO, suggested that monoterpene hydrocarbons could be
important for neuroprotection (Corasaniti et al., 2007).
ANALGESIC EFFECTS
Capsaicin-induced nociceptive responses in the plantar surface of
the hindpaw were signiﬁcantly reduced by intraplantar injection
of BEO. Further experiments addressed the importance of linalool
in BEO oil-induced antinociception (Sakurada et al., 2009). In
another study, injection into the hindpaw of both the linalool
and linalyl acetate compounds showed a signiﬁcant reduction of
nociceptive responses, which was much more potent than that
induced by BEO. The enhanced effect of the association of BEO or
linalool with morphine was antagonized by pretreatment with the
opioid antagonist naloxone (Sakurada et al., 2011). The analgesic
effect was also investigated using intraplantar injection of BEO or
linalool in mice with neuropathic hypersensitivity induced by par-
tial sciatic nerve ligation (PSNL). The results suggested that both
BEO and linalool reduced PSNL-induced mechanical allodynia in
a dose-dependent manner through a local effect. Moreover, the
analgesic effect was associated with a reduction of spinal extracel-
lular signal-regulated protein kinase (ERK) activation (Kuwahata
et al., 2013).
CARDIOVASCULAR PROPERTIES
Bergamottine signiﬁcantly decreased the electrocardiographic
changes that are typical of coronary arterial spasms and the occur-
rence of experimental cardiac arrhythmias provoked by pitressin
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in guinea pigs. Bergamottine also increased the dose of ouabain
required to cause ventricular premature beats, ventricular tach-
yarrhythmias, and death. These results indicate that bergamottine
possesses potential antianginal and antiarrhythmic properties
(Occhiuto and Circosta, 1996).
It is known that lectin-like oxyLDL receptor-1 (LOX-1) is
involved in smooth muscle cell proliferation and neo-intima for-
mation occurring in injured blood vessels. Interestingly, in an
experimentalmodel of rat angioplasty, pretreatmentwith the non-
volatile fraction of BEO, reduced the neointima proliferation in a
dose-dependent manner, together with free radical formation and
LOX-1 expression (Mollace et al., 2008). Moreover, it has been
suggested that BEO induces vasorelaxation of the mouse aorta by
activating K+ channels and inhibiting Ca2+ inﬂux (Kang et al.,
2013), which differentially modulates intracellular Ca2+ levels in
vascular endothelial and smooth muscle cells (You et al., 2013).
These ﬁndings indicate that BEO could be further studied for its
potential role as a vasodilator agent in cardiovascular diseases.
CLINICAL STUDIES
The scientiﬁc rationale of essential oils use in aromatherapy
to improve mood and the mild symptoms of stress disorders,
such as anxiety, depression, and chronic pain, is supported
by both the physiological and psychological effects caused by
the inhalation of volatile components that are believed to act
via limbic system structures, such as the hippocampal forma-
tion, the hypothalamus and the pyriform cortex. Indeed, several
clinical and experimental data indicate that aromatherapy can
improve mood, alertness, and cognition. Speciﬁc EEG changes
associated with alertness and relaxation have been observed in
some studies using essential oils. With regard to BEO, these
effects have been attributed to volatile components other than
5-MOP (Bagetta et al., 2010). Although the mechanisms by
which BEO induces its effects on the central nervous system
have not yet been fully understood, it has been suggested
that they could be mediated by the release of amino acids
that interact with mechanisms that modulate synaptic plastic-
ity (see neuropsychopharmacological and neuroprotective activities
section).
Clinical research focused essentially on the therapeutic appli-
cation of BEO in aromatherapy, by inhalation or hand massage,
on anxiety and stress responses. We reviewed the results of ten
clinical studies in which only two reported negative results. Their
principal data are reported in Table 1. Four studies evaluated the
effects of different essential oil combinations, with BEO being a
constituent of the mixture associated with lavender (Lavandula
angustifolia), cedarwood (Cedrus atlantica), ylang ylang (Cananga
odorata) or frankincense (Boswellia carteri; Graham et al., 2003;
Hwang, 2006; Chang, 2008; Hongratanaworakit, 2011). Among
the studies with combinations, only Graham et al.’s (2003) study
reported negative results. The other three studies showed positive
effects based on the subjective responses to stress. The remain-
ing six studies were all conducted using only BEO. Five of these
studies reported beneﬁcial effects from BEO, such as reduced
heart rate, blood pressure and stress responses (Peng et al., 2009;
Seo, 2009; Chang and Shen, 2011; Liu et al., 2013; Ni et al.,
2013). One study investigating the effects of aromatherapy with
BEO on pain and nausea of children and adolescents undergo-
ing stem cell transplantation, showed no beneﬁt. Unfortunately,
most of clinical trials did not report the quality parameters of
the essential oils used. Even though these studies are not always
satisfactory from a methodological point of view, they show that
employment of BEO in aromatherapy can be useful for reduc-
ing anxiety and stress responses, and it deserves further clinical
investigation.
PRE-CLINICAL SAFETY OF BEO
Bergamot essential oil is a widely used aromatic ingredient in cos-
metics that may be applied on sun-exposed skin areas, although
components such as bergapten, citropten, bergamotene, and other
furocoumarins may cause phototoxic effects (Chouchi et al., 1996;
Kejlovà et al., 2007). Indeed, psoralen can induce skin cancer due
to the formation of covalent DNA adducts by exposure to ultra-
violet A or solar light (Bakkali et al., 2008). On the contrary, it
was reported the photochemoprotection fromUVR-inducedDNA
damage by bergapten (Chadwick et al., 1994). Primarily due to the
presence of psoralens, BEO preparations may pose phototoxic,
genotoxic and carcinogenic risks. However, a layer of oil on the
skin has no sensitizing effect, if not rubbed in, and it has been
showedasBEOalonedoesnot irritate the skin (Oppenheim,1947).
Moreover, Trombetta et al. (2010) studied the genotoxic activity
of ethanolic bergamot extracts in the SOS (group of cellular func-
tions) chromotest (a bacterial test for detecting DNA-damaging
agents), which employs the error-prone DNA repair pathway of
E. coli PQ37. The experimental results suggested that the extracts,
used at doses up to 50 μg/assay, do not induce genotoxicity, even
when undergoing metabolic activation. However, in order to guar-
antee safety, bergapten and other phototoxic components should
be removed from BEO, thus resulting a furocoumarin-free BEO.
Its use in cutaneous preparations can be considered safe, hav-
ing no risk of such skin reactions (Belsito et al., 2007). However,
safety issues are not separate from the quality aspects regarding
the purity of the essential oil or the presence of adulterants. Anal-
ysis of BEO authenticity can be performed using enantioselective
gas-chromatography (Schipilliti et al., 2011).
ADVERSE EFFECTS
Despite its wide application, there are only a few reports of pho-
totoxic reactions caused by aromatherapy with BEO. Freund, in
1916, was the ﬁrst to describe a series of four cases of intense
pigmentation in irregular areas after the use of Eau de Cologne
before exposure to sunshine. He observed the same phenomenon
after experimental use of BEO, one of the constituents of Eau
de Cologne. Rosenthal ﬁrst used the term “Berloque dermatitis”
because of the form of the resulting pigmentation (Oppenheim,
1947). Hyperpigmentation of the neck, face, arms, or trunk that
have been exposed to light has been attributed to psoralens in the
BEO. Cases have become much more rare since the introduction
of psoralen-free BEO.
Bergamot essential oil rich in 5-MOP has been used as sun tan-
ning products for many years. In 1995, this use was banned and
limited to the treatment of certain skin disorders. Toxic reactions
can occur due to psoralen or UVA overdosing or due to acci-
dental exposure to additional UVA, including sunlight exposure.
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Skin application of psoralens is more likely to induce photosensi-
tivity reactions. To avoid the phototoxic and photocarcinogenic
harm, the International Fragrance Association (IFRA) recom-
mended that products that are applied in areas of skin exposed
to the sun not have to contain more than 0.4% of BEO.The occur-
rence of second-degree skin burns was found in two women after
PUVA exposure (Herr et al., 2007).
The cases of the two patients were described as having localized
anddisseminated bullous phototoxic skin reactions that developed
48–72 h after ultraviolet exposure subsequent to aromatherapy
with BEO. The ﬁrst case was of a woman that had used a berg-
amot aromatherapyoil preparation 3days earlier and subsequently
stayed exposed to the sun for several hours. In the second case, the
woman visited a sauna 2 days before, where she was exposed to
aromatherapy with BEO before being exposed to UVA radiation
while tanning. Cutaneous lesions developed gradually within 48–
72 h. In both cases, the patients did not use other creams and/or
medications at the same time (Kaddu et al., 2001).
In another case, a 44-year-old man drank up to 4 L of black
tea every day for 25 years. When he changed his brand because of
occasional gastric pain, he began to drink the same daily quan-
tity of Earl Gray tea. One week after the change, he noticed
repeated muscle cramps. After 5 weeks of drinking the tea, the
muscle cramps continued. Occasionally, he observed fascicula-
tions, distal paraesthesia, and feelings of pressure in his eyes
that were associated with blurred vision. Neurological exami-
nation conﬁrmed reduced visual acuity and fasciculations. After
5 months, suspecting a relation between his symptoms and his
tea intake, he stopped drinking Earl Gray, going back to black
tea. Within 1 week, the symptoms completely disappeared. Suc-
cessively, he observed that the symptoms did not appear if he
ingested no more than 1 L of Earl Gray tea each day. Earl Gray
tea is composed of black tea and BEO. The adverse effects of
BEO in this patient could be explained by the potential effects
of bergapten as a selective axolemmal potassium channel blocker,
reducing potassium permeability at the nodes of Ranvier in a
time-dependent manner. This may provoke hyperexcitability of
the axonal membrane and phase alterations of potassium cur-
rents, producing fasciculation and muscle cramps. Impairment
of the potassium channel function plays a pathogenic role in
other disorders characterized by the occurrence of fascicula-
tion. Prolonged opening of voltage-gated sodium channels caused
by bergapten may enhance neuronal hyperexcitability (Finsterer,
2002).
CONCLUSION
Bergamot essential oil has been traditionally used in Italian folk
medicine for magisterial, handcrafted, and homemade prepa-
rations that are intended for topical use as antiseptics for the
disinfection of skin and as aids for healing minor wounds. BEO
is generally well tolerated, but it possesses photosensitive proper-
ties because of the presence of furocoumarins, especially 5-MOP.
Therefore, in topical preparations, psoralen-free essential oil was
used in recent decades. As a consequence of this and because of
safety concerns related to furocoumarins, the use of high quality
controlled psoralen-free BEO is recommended as a general precau-
tion. However, although the oil has been used extensively for many
years, there have only been a few reports of phototoxic reactions
to bergamot aromatherapy oil.
Several biological activities of BEO were shown, such as
antimicrobial, anti-inﬂammatory, antiproliferative, and analgesic
effects, including effects on the central nervous and cardiovascu-
lar systems. Even though these effects indicate potential clinical
applications for BEO in the future, to date, only clinical studies
investigating aromatherapy effects have been published. The latter
were carried out primarily to investigate anxiolytic effects and the
reduction of stress responses. They indicate that treatment with
BEO in aromatherapy can be useful to reduce anxiety and stress
effects.
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